A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
545actual
Sites
106
Countries
Canada, France, Germany +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2015-05-06 | actual | When the study began enrolling |
| Primary completion | 2019-01-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2015-04-08 | estimated | When this record first appeared on the registry |
| Results posted | 2020-03-04 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-01-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Non-Small Cell Lung Cancer
Interventions
- Drug: Ramucirumab — also filed as LY3009806
- Drug: Placebo
- Drug: Erlotinib
- Drug: Gefitinib
- Drug: Osimertinib
Primary outcomes
what the primary-completion date above is the date OFPart B: Progression Free Survival (PFS)
measured Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months)
Number of Participants With Treatment-Emergent Adverse Events
measured Cycle 1 Day 1 through End of Study (Up To 3 Years)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocol: Protocol I4T-MC-JVCY(f)posted 2018-04-23 · 9.1 MB · Prot_000.pdf
Study Protocol: Protocol Addendum I4T-MC-JVCY(9)posted 2017-08-15 · 800 KB · Prot_002.pdf
Statistical Analysis Planposted 2018-12-13 · 647 KB · SAP_001.pdf
Publications
- PMID 40995949 — linked by the registry
- PMID 40458541 — linked by the registry
- PMID 39622410 — linked by the registry
- PMID 37691865 — linked by the registry
- PMID 37390764 — linked by the registry
- PMID 37329423 — linked by the registry
- PMID 35841410 — linked by the registry
- PMID 35369607 — linked by the registry
- PMID 34928484 — linked by the registry
- PMID 34795131 — linked by the registry
- PMID 31591063 — linked by the registry
- PMID 29317191 — linked by the registry
- PMID 27894601 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed